Drug developer 9 Meters Biopharma and its units have filed for Chapter 11 bankruptcy protection, it said in a regulatory filing on Tuesday, sending its shares tumbling 66% in premarket trading.

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it will be executing a ...

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President ...

Drug developer 9 Meters Biopharma and its units have filed for Chapter 11 bankruptcy protection, it said in a regulatory filing on Tuesday, sending its shares tumbling 66% in premarket trading.

9 Meters had reported cash and equivalent reserves of about $7 million as of March end. Its latest disclosure comes just months after it said it was preparing to test an obesity drug candidate, NM ...

9 Meters also raised a $5 million direct offering in mid-March that was slated to fund both further development of vurolenatide and NM-136. But the company was also contending with a lender that ...

9 Meters Biopharma NMTR was up 31.7% pre-market on Sep 27, after the company announced top-line results from its phase II study of its lead candidate, vurolenatide.

9 Meters now hopes to start a phase 3 programme for the drug before the end of the year, but the announcement has not been able to reverse a steady decline in its stock price since it reported ...